Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

HIV therapy

- PMLiVE

How is the vaccine reimbursement environment changing?

By Claire Woon

AMICULUM

- PMLiVE

Pfizer’s RSV vaccine candidate accepted for FDA priority review for use in older adults

A phase 3 study showed the vaccine was 85.7% effective in those with three or more symptoms

- PMLiVE

Moderna’s bivalent Omicron-targeting boosters show superiority to original COVID-19 vaccine

Both boosters produced a better immune response against Omicron BA.4/BA.5 subvariants

- PMLiVE

Pfizer’s maternal RSV vaccine candidate shows promise in phase 3 trial

The company stopped the trial early and plans to file for US approval by the end of 2022

- PMLiVE

GSK’s respiratory syncytial virus older adult vaccine given Priority Review by FDA

There are currently no RSV vaccines approved for older adults anywhere worldwide

- PMLiVE

GSK’s application for its RSV vaccine accepted by EMA under accelerated assessment

The vaccine demonstrated overall efficacy of 82.5% in adults aged 60 years and older

- PMLiVE

GSK’s shingles vaccine demonstrates at least ten-year efficacy in long-term study

ZOSTER-049 follows participants from two phase 3 trials for an additional six years

- PMLiVE

Pfizer/BioNTech announce positive early data from trial of BA.4/BA.5 COVID-19 booster

A 30µg dose of the booster demonstrated a ‘substantial increase’ in antibody response

- PMLiVE

WHO announces recommended 2023 flu vaccines for southern hemisphere

The constantly evolving nature of influenza viruses requires frequent reformulation of vaccines

- PMLiVE

Pfizer doses first patients with mRNA-based influenza vaccine

Available vaccine strains that match circulating influenza viruses offer only 40%-60% protection

- PMLiVE

Moderna sues Pfizer/BioNTech over COVID-19 vaccine technology

The company believes two key features of its patented mRNA technology platform were copied

- PMLiVE

Pfizer and BioNTech release COVID-19 vaccine trial results for children under five

The phase 2/3 trial results showed that the vaccine was 73.2% effective in protecting children aged six months to four years

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links